Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

dition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval, including with respect to TREANDA; manufacturing development and capabilities; market prospects for its products, including with respect to AMRIX; sales, adjusted net income and basic adjusted income per common share guidance for 2007 and 2008; and other statements regarding matters that are not historical facts, including the Company's position and expected performance in 2007 and 2008, the final resolution or outcome of the ongoing investigations by the U.S. Attorney's Office and the Office of the Connecticut Attorney General and the final amount of any settlement and/or fines related thereto, and the relative strength of the foundation for the Company's ongoing compliance efforts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermo
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 One of ... rise of personalized medicine, which is the practice of ... treatments to a patient,s individual biology. Personalized diagnostics—laboratory analyses ... major role in the lab,s future. This fall, ... feature the latest science in this exciting field and ...
(Date:8/1/2014)... Once a decision has been made ... will discuss how to define your tolerance for lowest ... Allen, Senior Director of Facilities Integration at Fluor Industrial ... Industrial Services, and special guest Carrier Li, Director in ... as they provide an examination of the Conceptual Design ...
(Date:8/1/2014)... 01, 2014 Testing the mechanical ... a better understanding embryonic development. How and ... structurally and functionally distinct tissues is important because ... Prof. Todd McDevitt, Melissa Kinney, and Rabbia Saeed ... with biochemical cues to control many aspects of ...
(Date:7/31/2014)... CHICAGO , July 31, 2014 Nearly ... 65 th Annual Meeting & Clinical Lab Expo ... The meeting featured never-before-seen breakthroughs in diagnostic research and ... treatment they need. As of Wednesday, July ... 2014 AACC Annual Meeting & Clinical Lab Expo, with ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Study Links Biomechanics and Gene Expression in Stem Cells 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3
... business has some sort of method of disposing of its old ... them to an asset management company, leasing firm, or recycler. It ... does your home look like? Are your closets or basements cluttered ... forever lost its remote? , ,The difference may be due to ...
... July 2006 edition of MedAd News sustains that the ... Aug, 23, 2004, I wrote an article for this publication on ... " , ,In this article I reviewed a number of key ... back to the 1970s and perhaps the year Genentech and Amgen ...
... - Dane County political and economic development leaders have ... of the area Collaboration Council has surpassed the $1 million ... once faced even greater regional challenges than Dane County. , ... president of the Metro Denver Economic Development Corp ., ...
Cached Biology Technology:Computer recycling: An environmental mandate the private sector can support 2Computer recycling: An environmental mandate the private sector can support 3Computer recycling: An environmental mandate the private sector can support 4At 30, biotech is an industry at a crossroads 2At 30, biotech is an industry at a crossroads 3At 30, biotech is an industry at a crossroads 4At 30, biotech is an industry at a crossroads 5At 30, biotech is an industry at a crossroads 6At 30, biotech is an industry at a crossroads 7Can Dane Co. and Wisconsin learn from Denver? 2Can Dane Co. and Wisconsin learn from Denver? 3Can Dane Co. and Wisconsin learn from Denver? 4
(Date:7/31/2014)... Foundation (NSF), counters a widely-held scientific view that ... that certain Arctic lakes store more greenhouse gases ... The study, published this week in the journal ... occur as permafrost thaws and creates surface depressions ... was previously frozen land into lakes. , The ...
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... cap is good for you, at least if you are ... in Oncology Center have shown that in healthy cells, a ... genetic storehouse, in its proper place. Understanding this cap,s influence ... clues to the diagnosis and treatment of diseases such as ...
... , REDWOOD CITY, Calif., Dec. 2 DigitalPersona, Inc., ... announced an agreement with IBM to deploy a new ... SurePOS 500 retail systems. The DigitalPersona U.are.U® 4500HD offering ... users so that specific transactions can be linked to ...
... prescribed beta 2 adrenergic agonist drugs for the treatment of ... increase the incidence of autism-spectrum disorders, psychiatric pathology, cognitive problems ... new study published in the December 2009 issue of the ... 2 adrenergic agonist drugs as a class are widely used ...
Cached Biology News:A cell's 'cap' of bundled fibers could yield clues to disease 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2